medigraphic.com
ISSN 2448-8909 (Impreso)

2000, Número 6

<< Anterior Siguiente >>

Med Crit 2000; 14 (6)


Síndrome de insuficiencia respiratoria aguda tardío Una entidad emergente

Carrillo ER

Idioma: Español
Referencias bibliográficas: 68
Paginas: 203-214
Archivo PDF: 389.04 Kb.


RESUMEN

Objetivo: Reportar nuestra experiencia en el tratamiento del SIRA tardío con metilprednisolona.
Diseño: Serie de casos.
Lugar: UCI de un hospital de tercer nivel de la Ciudad de México.
Pacientes: Seis pacientes (tres mujeres, tres hombres, edad media 35.1 años) con SIRA.
Intervenciones: Monitoreo invasivo, biopsias pulmonares, broncoscopias, ventilación mecánica y metilprednisolona.
Mediciones y resultados principales: Dos pacientes murieron. En la 4ª semana de estancia se observó en los sobrevivientes, PaO2/ FIO2 380, Qs/Qt 5%, índice de Murray 0 puntos, índice de resistencias vasculares pulmonares 100 din. s/cm-5 , índice cardiaco 3 L/min, distensibilidad 63 cm H2O, daño alveolar difuso y trombosis de vasos pequeños pulmonares; y en los no sobrevivientes PaO2/FIO2 110, Qs/Qt 43%, índice de Murray 4 puntos, índice de resistencias vasculares pulmonares 280 din. s/cm-5, índice cardiaco 4 L/min, distensibilidad 23 cm H2O, fibrosis extensa con pérdida de la arquitectura alveolar y vascular.
Conclusión: La metilprednisolona puede ser útil en el tratamiento del SIRA tardío.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Levy PC, Utell MJ, Sickei JZ et al. The acute respiratory distress syndrome: current trends in pathogenesis and management. Compr Ther 1995; 21: 438-444.

  2. Petty TL. The acute respiratory distress syndrome: historical perspective. Chest 1994; 105 (Suppl): 44S-47S.

  3. Suter PM, Suter S, Girardin E et al. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022.

  4. Meduri GU. Thrue role of the host defense response in the progression and outcome or ARDS: pathophysiological correlations and respond to glucocorticoid treatment. Eur Respir J 1996; 9: 2650-2670.

  5. Milberg JA, Davis DR, Steinberg KP et al. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273: 306-309.

  6. Montgomery AB, Stager MA, Carrico CJ et al. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132: 485-489.

  7. Sukchyta MR, Clemmer TP, Elliott CG et al. The adult respiratory distress syndrome. A Report of survival and modifyng factor. Chest 1992;101:1074-1079.

  8. Bone RC, Balk R, Slotman G et al. Adult respiratory distress syndrome. Sequence and importance of development of multiple organ failure. Chest 1992; 101: 320-326.

  9. Seidenfel JJ, Pohll DF, Bell RC et al. Incidence, site, and outcome of infections in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1986; 134: 12-16.

  10. Meduri GU, Belenchia JM, Ester RJ et al. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids. Chest 1991; 100: 943-952.

  11. Headley S, Meduri GU, Stenz F et al. Unfavorable outcome in patients with ARDS is related to persistent release of inflammatory cytokines. Abstr. Chest 1993; 104(Suppl): 154S.

  12. Donelly SC, Strieter RM, Kinkel SL et al. Inerleukin -8 and development of adult respiratory distress syndrome in atrisk patient groups. Lancet 1993; 341: 643-647.

  13. Meduri GU, EL Torki M et al. The fibroproliferative phase of late adult respiratory distress syndrome. Semin Respir Infec 1995; 10: 154-175.

  14. Meduri GU, Kohler S, Headley E et al. Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevations over time predicts poor outcome. Chest 1995; 108: 1303- 1314.

  15. Artigas A, Bernard GR, Carlet J, Dreyfuss D, Hudson L etal. The American-European Consensus Conferenced on ARDS, Part 2. Int Care Med 1998; 24: 378-398.

  16. Meduri GU. Late adult respiratory distress syndrome. New Hor 1993; 1: 563-577.

  17. Murray JF, Matthay MA, Luce JM. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988; 138: 720-23.

  18. Ausbaugh DG, Maier RV. Idiopathic pulmonary fibrosis in adult respiratory distress syndrome, diagnosis and treatment. Arch Surg 1985; 120: 530-535.

  19. Meduri GU, Mauldin GL, Wunderink R et al. Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator- asociated pneumonia. Chest 1994; 106: 221-35.

  20. Kovacs EJ, Dipietro LA. Fibrogenic cytokines and conective tissue production. FASEB J 1994; 8: 854-861.

  21. Elias J, Frendlich B, Kern JA et al. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest 1995; 97: 1439-45.

  22. Meduri GU, Tolley EA, Chinn A et al. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methilprednisolone treatment. Am J Respir Crit Care med 1998; 158: 1432-1441.

  23. Entzian P, Huckstad H et al. Determinations of serum concentrations of type III procollagen peptide in mechanically ventilated patients: pronounced augmented concentrations in the adult respiratory distress syndrome. Am Rev Resp Dis 1990; 142: 1076-1082.

  24. Clark JG, Miberg KP, Steinberg et al. Type III procollagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with increased risk for death. Ann Intern Med l992; 122: 17-23.

  25. Fukuda Y, Ishizaki M, Masuda Y et al. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987; 126: 171-182.

  26. Tomaseski JF, Davies P, Boggis C et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983; 112: 112-125.

  27. Waydhas C, Nast-Kolb D, Trupka A et al. Increased serum concentrations of procollagen type III peptide in severely injured patients: An indicator of fibrosing activity? Crit Care Med 1993; 21: 240-247.

  28. Tomaseski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med l990; 11593-619.

  29. Kelly J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-88.

  30. Kohler G, Meduri GU, Stntz F et al. Inflammatory cytokines in tha BAL of ARDS. Abstr Chest 1993; 104(Suppl): 151S.

  31. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Car Med 1996; 24: 163-72.

  32. Casey LC, Balk RA. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119: 771-78.

  33. Pittet JF, Mackersie R, Martin TR et al. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155: 1187-1205.

  34. Martin TR. Cytokines and the acute respiratory distress syndrome (ARDS): a question of balance. Nat Med 1997; 3: 272-273.

  35. Miller EJ, Nagao S, Griffith D et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and areassociated with increased mortality. Am Rev Respir Dis 1992; 146: 427-432.

  36. Papanicolaou DA, Wilder RL, Manolagas SC et al. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.

  37. Pugin J, Ricou B, Steinber KP et al. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent fole for interleukin-1beta. Am J Respir Crit Care Med 1996; 153: 1850-1856.

  38. Meduri GU, Kohler G, Headley S et al. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts outcome. Chest 1995; 108: 1303-1314.

  39. Clark JG, Milberg JA, Steinberg KP et al. Type III procolagen peptide in the adult respiratory distress syndrome: association of increased peptide levels in bronchoalveolar lavage fluid with inreased risk for eath. Ann Intern Med 1995; 122: 17-23.

  40. Chesnutt AN, Matthay MA, Tibayan FA et al. Early detection of type III procollagen peptide in acute lung injury: pathogenetic and prognostic significance. Am J Respir Crit Care Med 1997; 156: 840-845.

  41. Berton G, Yan SR, Fumagalli L et al. Neutrophil activation by adhesion: mechanisms and pathophysiological implications. Int J Clin Lab Res 1996; 26: 160-177.

  42. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147.

  43. Repine JE, Beehler CJ. Neutrophils and the adult respiratory distress syndrome: two interlocking perspectives. Am Rev Respir Dis 1991; 144: 251-252.

  44. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15: 675-705.

  45. Meduri UG, Headley S, Koffier G et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: plasma IL-1b and IL-6 are consistent and efficient predictor of outcome over time. Chest 1995; 107: 1062-1073.

  46. Martin TR, Goodman RB. The role of chemokines in the pathophysiology of the acute respiratory distress syndrome (ARDS). In: Hebert C, ed. Chemokines in disease. New York, NY: Humana Press 1999; 81: 81-110.

  47. Elenkow I, Papanicolaou D, Wilder RL et al. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production. Proc Assn Am Phys 1996; 108: 374-381.

  48. Wissink S, van Heerde EC, van der Burg B et al. A dual mechanism mediated repression of NF-kB activity by glucocortidoids. Mol Endocrinol 1998; 12: 355-363.

  49. Albina JE, Reichner JS. Nitric oxide in inflammation and immunity. New Hor 1995; 3: 46-64.

  50. Hart PH, Whitty GA, Burgess DR et al. Augmentation of glucocorticoid action on human monocytes by interleukin-4. Linphokine Researech 1990; 9: 147-153.

  51. Guirao X, Lowry SF. Biologic control of injury and inflammation: much more than too little of too late. World J Surg 1996; 20: 437-446.

  52. Meduri GU. Levels of evidence for the pharmacologic effectiveness of prolonged methylprednisolone treatment in un resolving ARDS. Chest 1999; 116: 116S-118-S.

  53. Meduri GU, Chinn AJ, Leeper KV et al. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS: patterns of response and predictors of outcome. Chest 1994; 105: 1516-1527.

  54. Meduri GU, Chrousos GP. Durat ion of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998; 114: 355-360.

  55. Meduri GU, Headley S, Carson S. Prolonged methylprednisolone treatment improves lung function and outeome of unresolving ARDS: a randomized, double-blind, placebocontrolled trial. JAMA 1998; 280: 159-165.

  56. Hooper RG, Kearl RA. Established ARDS treated with a sustained course of adrenocortical steroids. Chest 1990; 97: 138-43.

  57. Postlethwaite AE, Holness MA, Katai H et al. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992; 90: 1479-85.

  58. Liu LY, Sun B, Tian Y et al. Changes of pulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion. Am Rev Respir Dis 1993; 148: 878-81.

  59. Zitnik RJ, Whiting NL, Elias JA. Glucocorticoid inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts: evidence for transcriptional and posttranscriptional regulatory mechanisms. Am J Respir Cell Mol Biol 1994; 10: 643-50.

  60. Auler JOC, Calheiros DF, Brentain MM et al. Adult respiratory distress syndrome evidence of early fIbrogenesis and absence of glucocorticoids receptor. Eur J Respir Dis 1986; 69: 261-69.

  61. Saldiva PH, Brentani MM, De Carvalho CRR. Changes in the pulmonary glucocorticoid receptor content in the course of interstitial lung disease. Chest 1985; 88: 417-19.

  62. Meduri GU, Leeper KV, Tolley E, Stentz F, Headley S, Kohier G. Inflaminatoty cytokines response to high-dose corticosteroids in late ARDS. Chest 1993; 104: 12S

  63. Hill JD, Ratliff JL, Parrot JCW et al. Pulmonary pathology in acute respiratory insufficiency: fung biopsy as a diagnostic tool. J Thorac Cardiovasc Surg 1976; 71: 64-71.

  64. Warner DO, Warner MA, Divertie MB. Open lung biopsy in patients with diffuse pulmonary infiltrates and acute respiratory distress failure. Am Rev Respir Dis 1988; 137: 90-94.

  65. Nelems JM Cooper JD, Henderson MB, Peng T, Phillips MJ. Emergency open lung biopsy. Ann Thorac Surg 1976; 260-64.

  66. Seidenfield JJ, Pohi DF, Bell RC, Harris GD, Johanson WG Jr. Incidence, site, and outeome of infections in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1986; 134: 12-16.

  67. Fagon JY, Chastre J, Domart Y, Trouillet JI, Pierre J, Darne C et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139: 877-84.

  68. Meduri GU. Ventilator-associated pneumonia in patients with respiratory failure: a diagnostic approach. Chest 1990; 97: 1208-19.




2020     |     www.medigraphic.com